Giant Cell Glioblastoma
|
0.510 |
GeneticVariation
|
disease |
BEFREE |
Our data indicate, that in addition to the histological and immunohistochemical evaluation, investigation of MGMT promoter methylation and in particular BRAF V600E mutations represent reliable additional tools to sustain differentiation of gcGBM from PXA on a molecular basis.
|
27253461 |
2016 |
Giant Cell Glioblastoma
|
0.510 |
Biomarker
|
disease |
ORPHANET |
A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma.
|
22380407 |
2012 |
Giant Cell Glioblastoma
|
0.510 |
Biomarker
|
disease |
CTD_human |
Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.
|
22162573 |
2012 |
Giant Cell Glioblastoma
|
0.510 |
Biomarker
|
disease |
ORPHANET |
O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications.
|
20556478 |
2011 |
Giant Cell Glioblastoma
|
0.510 |
Biomarker
|
disease |
CTD_human |
MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma.
|
20131314 |
2010 |
Brain Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Since new diagnostic methods such as methylome-based classification of brain tumors are more and more frequently performed, we aimed at comparing the suitability of calculating the MGMT promoter methylation status in a quantitative manner from the methylome profiling as compared to the classic gold standard assessment by PCR.
|
31784096 |
2020 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter hypermethylation was detected in 38.7% of glioblastoma patients.
|
31701343 |
2020 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The CpG methylation status of the MGMT promoter strongly correlates with clinical outcome and, therefore, is used as prognostic marker during glioblastoma therapy.
|
31395346 |
2020 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we quantify baseline expression of MGMT and EGFR protein in newly diagnosed GBM samples using mass spectrometry.
|
31823165 |
2020 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The results confirm that the quantitative level of MGMT promoter methylation is a positive prognostic factor in newly diagnosed patients with GBM.
|
31422371 |
2020 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Histological examination confirmed a wild-type (WT) IDH1/2, MGMT (DNA repair enzyme O6-methylguanine-DNA methyltransferase) methylated glioblastoma with a proliferative index focally as high as 20%.
|
31173153 |
2020 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT methylation appears to convey a survival benefit in the setting of bevacizumab treatment for progressive GBM.
|
31756059 |
2020 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
In addition to its benefits for molecular subgrouping and copy number analysis of brain tumors, DNA-methylation based classification is a highly reliable tool for the assessment of MGMT promoter methylation status in glioblastoma patients.
|
31784096 |
2020 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
• ASL-PWI can aid to predict IDH and MGMT promoter methylation statuses in GBM.
|
31468161 |
2020 |
Glioma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
<i>O</i>(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation is a high predictive factor for therapy results of temozolomide in patients with glioma.
|
31422371 |
2020 |
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT methylation appears to convey a survival benefit in the setting of bevacizumab treatment for progressive GBM.
|
31756059 |
2020 |
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
In addition to its benefits for molecular subgrouping and copy number analysis of brain tumors, DNA-methylation based classification is a highly reliable tool for the assessment of MGMT promoter methylation status in glioblastoma patients.
|
31784096 |
2020 |
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The results confirm that the quantitative level of MGMT promoter methylation is a positive prognostic factor in newly diagnosed patients with GBM.
|
31422371 |
2020 |
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Some of these genetic alterations are currently believed to have clinical significance and are more related to secondary GBMs: TP53 mutations, detectable in the early stages of secondary GBM (found in 65%), isocitrate dehydrogenase 1/2 mutations (50% of secondary GBMs), and also O6-methylguanine-DNA methyltransferase promoter methylation (75% of secondary GBMs).
|
31550738 |
2020 |
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The CpG methylation status of the MGMT promoter strongly correlates with clinical outcome and, therefore, is used as prognostic marker during glioblastoma therapy.
|
31395346 |
2020 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we quantify baseline expression of MGMT and EGFR protein in newly diagnosed GBM samples using mass spectrometry.
|
31823165 |
2020 |
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
• ASL-PWI can aid to predict IDH and MGMT promoter methylation statuses in GBM.
|
31468161 |
2020 |
Glioblastoma Multiforme
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Histological examination confirmed a wild-type (WT) IDH1/2, MGMT (DNA repair enzyme O6-methylguanine-DNA methyltransferase) methylated glioblastoma with a proliferative index focally as high as 20%.
|
31173153 |
2020 |
Glioblastoma Multiforme
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter hypermethylation was detected in 38.7% of glioblastoma patients.
|
31701343 |
2020 |
Brain Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Disulfiram has also been shown to inhibit the proteasomes, DNA topoisomerases, DNA methyltransferase, glutathione S-transferase P1, and O6- methylguanine DNA methyltransferase, a DNA repair protein highly expressed in brain tumors.
|
31084595 |
2019 |